A Sicras1, A Huerta2, R Navarro3, J Ibañez4. 1. Dirección de Planificación, Badalona Serveis Assistencials, Badalona, Barcelona, España. 2. Departamento de Evaluación de Medicamentos, GlaxoSmithKline, Madrid, España. Electronic address: alicia.h.huerta@gsk.com. 3. Servicio de Documentación, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, España. 4. Dirección Médica, Badalona Serveis Assistencials, Badalona, Barcelona, España.
Abstract
OBJECTIVE: Exacerbations are a clinical characteristic of chronic obstructive pulmonary disease (COPD). The objective of the study was to estimate the resource use and costs associated with COPD exacerbations PATIENTS AND METHODS: Observational study performed by retrospective review of patient clinical charts of a Hospital and 6 associated Primary Care Centers. COPD patients >40years old who were followed-up during 2010-2011, and who fulfilled inclusion/exclusion criteria were included in the study. Healthcare resource use and costs associated to COPD exacerbations (moderate/severe) were estimated. Healthcare resource use, loss of productivity and costs associated to the follow-up of COPD patients (with/without exacerbations) were also estimated. STATISTICAL ANALYSIS: regression model and ANCOVA, P<.05. RESULTS: A total of 1,210patients were included in the study, of whom 51.2% experienced an exacerbation, and with an average of 4exacerbations/patient. Presence of exacerbations was associated with age, COPD severity, presence of comorbidities, and time from diagnosis. The average healthcare cost of an exacerbation was €481 (moderate: €375; severe: €863). Patients who experienced an exacerbation had a higher resource use and costs (P<.001). Thus, the follow-up cost of patients without exacerbations was €1,392 versus €3,175 for patients with exacerbations. CONCLUSION: The presence of exacerbations in COPD patients was associated with an increase in resource use and associated costs.
OBJECTIVE: Exacerbations are a clinical characteristic of chronic obstructive pulmonary disease (COPD). The objective of the study was to estimate the resource use and costs associated with COPD exacerbations PATIENTS AND METHODS: Observational study performed by retrospective review of patient clinical charts of a Hospital and 6 associated Primary Care Centers. COPDpatients >40years old who were followed-up during 2010-2011, and who fulfilled inclusion/exclusion criteria were included in the study. Healthcare resource use and costs associated to COPD exacerbations (moderate/severe) were estimated. Healthcare resource use, loss of productivity and costs associated to the follow-up of COPDpatients (with/without exacerbations) were also estimated. STATISTICAL ANALYSIS: regression model and ANCOVA, P<.05. RESULTS: A total of 1,210patients were included in the study, of whom 51.2% experienced an exacerbation, and with an average of 4exacerbations/patient. Presence of exacerbations was associated with age, COPD severity, presence of comorbidities, and time from diagnosis. The average healthcare cost of an exacerbation was €481 (moderate: €375; severe: €863). Patients who experienced an exacerbation had a higher resource use and costs (P<.001). Thus, the follow-up cost of patients without exacerbations was €1,392 versus €3,175 for patients with exacerbations. CONCLUSION: The presence of exacerbations in COPDpatients was associated with an increase in resource use and associated costs.
Authors: Oskar Eklund; Faraz Afzal; Fredrik Borgström; Jason Flavin; Andrew Ternouth; Maria Eugenia Ojanguren; Carlos Crespo; Mike Baldwin Journal: Clinicoecon Outcomes Res Date: 2016-06-11
Authors: Antoni Sicras Mainar; Alicia Huerta; Ruth Navarro Artieda; Eduard Monsó; Sarah H Landis; Afisi S Ismaila Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-09-12
Authors: Marc Miravitlles; Juan B Gáldiz; Alicia Huerta; Alba Villacampa; David Carcedo; Francisco Garcia-Rio Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-01-18